Petr T.
- Country
- Czechia
- Department
- Dermatovenerologicka ambulance
Research Overview
- A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherapy compared with placebo in subjects with moderate-to-severe atopic hand eczema who are candidates for systemic therapy (ADHAND)
- Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis
- Long-term Safety, Efficacy, and Response Durability of Envudeucitinib in Moderate to Severe Plaque Psoriasis: An Extension Study
Data & Insights
Has run more than one trial at 100 of 362 partner sites.
Specializations
Dermatological Conditions
This investigator specializes in treating complex dermatological conditions, with particular emphasis on moderate to severe plaque psoriasis and atopic dermatitis.
- Chronic Plaque Psoriasis Management
- Atopic Hand Eczema Treatment
- Inflammatory Skin Disorders
The investigator focuses on evaluating innovative therapeutic approaches for persistent skin conditions requiring systemic intervention.
Therapeutic Innovation
The investigator examines novel therapeutic agents including tralokinumab and ESK-001 for dermatological applications.
- Targeted Biological Therapies
- Long-term Treatment Safety
- Therapeutic Response Durability
Their work encompasses the evaluation of treatment efficacy for patients who require sustained therapeutic intervention.
Clinical Assessment
The investigator specializes in assessing treatment outcomes in dermatological conditions through systematic clinical evaluation.
- Disease Severity Assessment
- Treatment Response Monitoring
- Safety Profile Analysis
Their expertise includes evaluating therapeutic interventions for patients with moderate to severe dermatological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.